Industry Symposia at ECP 2021

Sunday, 29 August 2021 | 11:45 - 13:15 (CEST)

Chair: John Longshore, UK
Speakers: Silvia Novello | David Gonzales de Castro | John Gosney

 

Welcome and Introduction

John Longshore, USA

Medical Oncologist perspective: Rationale for biomarker profiling in patients with NSCLC

Silvia Novello, Italy

Clinical application of liquid biopsy in patients with NSCLC

David Gonzales de Castro, Spain

Principles and practicalities of reflex ordered testing for biomarkers in patients with NSCLC

John Gosney, United Kingdom

A testing strategy for timely and complete biomarker profiling

John Longshore, USA

Q&A session

John Longshore, USA

Chair: Guiseppe Viale
Speakers: Guiseppe Viale | Volkmar Müller | Frédérique Penault-Llorca | Josef Rüschoff

 

Welcome and meeting objectives

Giuseppe Viale, Italy

HER2-targeted molecules in development for patients with HER2-low breast cancer

Volkmar Müller, Germany

Changing the way we look at HER2-negative breast cancer

Frédérique Penault-Llorca, France

Digital pathology, RNA, proteomics and what else to identify HER2-low breast tumours?

Josef Rüschoff, Germany

Panel discussion and Q&A

All

Closing remarks

Giuseppe Viale, Italy

Chair: Angelo Dei Tos
Speakers: Rosario Garcia-Campelo | Wilko Weichert | Angelo Dei Tos

 

The role of MET inhibitors in the treatment of NSCLC: clinical benefits and practical considerations of genomic testing

Rosario Garcia-Campelo, Spain

Genomic testing in NSCLC: Current challenges and new approaches with focus on MET-testing

Wilko Weichert, Germany

Genomic testing in breast cancer: Lessons learned from NSCLC and future perspectives with focus on PIK3CA-testing

Angelo  Dei Tos, Italy

Q&A Session

Angelo Dei Tos, Italy

Chair: Rachel Butler
Speakers: Rachel Butler | Alexander Drilon | Rossella Elisei | Michelle Williams

 

Value of Comprehensive Profiling and the role of NTRK and RET in cancer pathology

Rachel Butler, United Kingdom

NSCLC cases from the clinic: Panel discussion

Alexander Drilon, USA | Rachel Butler, United Kingdom

Thyroid cancer cases from the clinic: Panel discussion

Rossella Elisei, Italy | Michelle Williams, USA | Rachel Butler, United Kingdom

Recommendations for optimal NTRK gene fusion and RET alteration detection

Michelle Williams, USA

Chair: Peter Wild
Speakers: Magali Lacroix-Triki | Anastasia Constantinidou | William Cross | Peter Wild

 

Benefits of second generation signatures: In-house measurement and integrated risk assessment

Magali Lacroix-Triki, France

Which premenopausal breast cancer patients can safely forego chemotherapy? Latest data for EndoPredict

Anastasia Constantinidou, Greece

Recent developments in molecular prognostics in the prostate cancer pathway

William Cross, United Kingdom

New local application for prostate cancer prognosis with Prolaris

Peter Wild, Germany

Q&A Session

Peter Wild, Germany

Speakers: Herve Avet-Loiseau | Andrew Spencer

 

Established & Emerging Prognostic Biomarkers in Multiple Myeloma

Herve Avet-Loiseau, France

Emerging Predictive Biomarkers in Multiple Myeloma
Andrew Spencer, Australia

Monday, 30 August 2021 | 6:45 - 7:45 (CEST)

Chair: John Longshore
Speakers: Shobhit Baijal | John Gosney

 

Welcome and Introduction

John Longshore, USA

Emerging molecular targets in the treatment of metastatic NSCLC

Shobhit Baijal, United Kingdom

Practical guidance for the testing of emerging molecular markers in metastatic NSCLC

John Gosney, United Kingdom

Discussion: Optimal workflow in a healthcare system to ensure all eligible lung cancer patients are NGS tested

John Longshore, USA | Shobhit Baijal, United Kingdom | John Gosney, United Kingdom

Q&A session

John Longshore, USA

Monday, 30 August 2021 | 11:45 - 13:15 (CEST)

Chair: Anders Edsjö
Speakers: Thomas McKee | Henrik Grönberg

 

Welcome and Introduction

Anders Edsjö, Sweden

Introducing the concept of homologous recombination deficiency

Anders Edsjö, Sweden

Integrating HRD genomic instability testing in ovarian cancer

Thomas McKee, Switzerland

How to optimise BRCA testing in prostate cancer

Henrik Grönberg, Sweden

Q&A Session

Anders Edsjö, Sweden

Chair: Aleš Ryška
Speakers: Frédérique Penault-Llorca |  Albrecht Stenzinger | Rafal Dziadziuszko

 

Welcome and introduction

Aleš Ryška, Czech Republic

Emerging targeted therapies in NSCLC

Rafal Dziadziuszko, Poland

Best practice in specimen processing and management

Frédérique Penault-Llorca, France

Best practice in biomarker testing and reporting

Albrecht Stenzinger, Germany

Interactive case studies and discussion

All

Q&A Session

All

Chair: Massimo Barberis
Speakers: Jon Sherlock | Javier Hernandez Loza | Peter Wild

 

The future of Precision Oncology with 1 Day NGS

Jon Sherlock, USA

The economic advantage of in house 1 day NGS

Javier Hernandez Losa

Algorithms to use different size of panels for different type of cancers - experience in a molecular pathology lab

Peter Wild, Germany

The role of Comprehensive genomic profiling in emerging biomarker testing

Nicola Normanno, Italy

Q&A Session

Massimo Barberis, Italy

Chair: Umberto Malapelle
Speakers: Anais Pujals | Umberto Malapelle | Audrey Lupo

 

Idylla™ MSI Assay as a new tool for the detection of microsatellite instability

Anais Pujals, France

Feasability of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy NSCLC samples

Umberto Malapelle, Italy

Multicenter study using the Idylla GeneFusion prototype cartridge

Audrey Lupo, France

Q&A Session

Umberto Malapelle, Italy

Chair: Manuel Salto-Tellez
Speakers: Manuel Salto-Tellez | Frederick Klauschen | Wilko Weichert

 

Applications of AI and the use of IHC Scoring algorithms in Pathology

Manuel Salto Tellez, United Kingdom

Is the use of Artificial or Augmented Intelligence (AI) the future of Pathology?

Frederick Klauschen, Germany

Utilization of IHC Scoring algorithms in pathology. Challenges and Opportunities

Wilko Weichert, Germany

Q&A Session

Manuel Salto Tellez, United Kingdom

Chair: Emilia Andersson
Speakers: Christopher Williams | Philip Quirke | Emilia Andersson

 

Christopher Williams, United Kingdom

Delivering biomarker results to the clinic

Philip Quirke, United Kingdom

Panel discussion

Emilia Andersson, Sweden | Christopher Williams, United Kingdom | Philip Quirke, United Kingdom

Tuesday, 31 August 2021 | 6:45 - 7:45 (CEST)

Chair: Jose Luis Costa
Speakers: Jose Luis Costa | Massimo Barberis

 

Introduction to multi-biomarker profiling: What is the data saying about it?

Jose Luis Costa, Spain

Multi-biomarker solution for tumor agnostic genomic profiling

 

Multicentric study to evaluate in-house solution for CGP

Massimo Barberis, Italy

Q&A session

Jose Luis Costa, Spain

Tuesday, 31 August 2021 | 12:45 - 14:15 (CEST)

Chair: Paul Hofman
Speakers: Paul Hofman | John Gosney | Ignacio Wistuba

 

Welcome and Introduction

Paul Hofman, France

Why the tissue will still be an issue: a review of current and future diagnostic demands for managing patients with NSCLC

Paul Hofman, France

Pathological diagnosis and molecular analysis with small biopsies and cytology: strategic management of the diagnostic biopsy

John Gosney, United Kingdom

Pathologic assessment of lung cancer resection specimens after neoadjuvant therapy

Ignacio Wistuba, USA

Q&A Session

Paul Hofman, France

Chair: Daniel Vaughan
Speakers: Virginie Goubert | Sneha Barry | Friedrich Feuerhake | David Mason

 

Introduction

Daniel Vaughan, United Kingdom

Transformative approaches in Spatial Biology for Biomarker Signature Discovery

Virginie Goubert, France

New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology

Sneha Berry, USA

Spatial Immunophenotyping in Clinical Trials: An Interdisciplinary Challenge in Translational Biomarker Research

Friedrich Feuerhake

Making Complex Analysis Simple with Visiopharm’s Multiplex Phenotyping Tools

David Mason, United Kingdom

Q&A Session

Daniel Vaughan, United Kingdom

Chair: Fernando Lopez-Rios-Moreno
Speakers: Vicente Peg | Fernandez Lopez-Rios-Moreno | Josef Rüschoff

 

Welcome and Introduction

Fernando Lopez-Rios, Spain

PD-L1 assay “interchangeability”: To do or not do? What have we learned?

Vicente Peg, Spain

Looking to the future: Emerging BMx landscape in cancer immunotherapy. Are we ready?

Fernando Lopez-Rios, Spain

Q&A Session

Faculty

MSI and MMR testing in Gynecological Versus GI cancers: What to know?

Josef Rüschoff, Germany

Q&A Session

Faculty

Closing Remarks

Fernando Lopez-Rios, Spain

Chair: Roberto Salgado
Speakers: Roberto Salgado | Cecily Quinn

 

Utility of genomic testing in real life to guide treatment decisions in breast cancer

Roberto Salgado, Belgium

Reflection of 10 years of Genomic testing

Cecily Quinn, Ireland

Q&A Session

Roberto Salgado, Belgium | Cecily Quinn, Ireland

Chairs: Paula Toro | Emilia Andersson
Speakers: Frédérique Penault-Llorca | Giuseppe Viale

 

Dialogue between experts: Controversies and unsolved issues in Breast Cancer

Frédérique Penault-Llorca, France | Giuseppe Viale, Italy

Chair: Xavier Matias-Guiu
Speakers: Angela George | Christoph Grimm | Xavier Matias-Guiu

 

Introduction
Xavier Matias-Guiu, Spain
Biomarker testing in endometrial cancer: Where we are today?

Angela George, United Kingdom

MMR/MSI testing: What are the practicalities, pros and cons?

Xavier Matias-Guiu, Spain
Live panel discussion with audience and Q&A

All

Biomarker testing for patients with endometrial cancer: What is the clinical relevance?

Cristoph Grimm, Austria

Live panel discussion with audience and Q&A

All